$CYDY
CytoDyn Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837025000207 Filed on January 14, 2025

View on sec.gov

Income Statement

Concept 2024 Q4 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $2.311M
YoY Change -54.17%
% of Gross Profit
Research & Development $1.079M
YoY Change 687.59%
% of Gross Profit
Depreciation & Amortization $4.000K $8.000K
YoY Change -50.0% -85.19%
% of Gross Profit
Operating Expenses $1.079M
YoY Change 687.59%
Operating Profit -$3.707M -$3.398M
YoY Change 9.09% -85.33%
Interest Expense -$1.326M
YoY Change -24.53%
% of Operating Profit
Other Income/Expense, Net -$1.797M
YoY Change 91.78%
Pretax Income -$4.768M -$9.563M
YoY Change -50.14% -63.91%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.768M -$9.563M
YoY Change -50.14% -63.91%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.01
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 1.221B 959.0M
Diluted Shares Outstanding 1.221B 959.0M

Balance Sheet

Concept 2024 Q4 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.0K
YoY Change -93.88%
Cash & Equivalents $21.34M $147.0K
Short-Term Investments
Other Short-Term Assets $8.693M
YoY Change 109.57%
Inventory
Prepaid Expenses $635.0K $1.578M
Receivables
Other Receivables
Total Short-Term Assets $24.63M $8.840M
YoY Change 178.65% 34.94%
LONG-TERM ASSETS
Property, Plant & Equipment $332.0K
YoY Change -29.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $244.0K $400.0K
YoY Change -39.0% -23.52%
Total Long-Term Assets $244.0K $400.0K
YoY Change -39.0% -23.52%
TOTAL ASSETS
Total Short-Term Assets $24.63M $8.840M
Total Long-Term Assets $244.0K $400.0K
Total Assets $24.88M $9.240M
YoY Change 169.23% 30.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.24M $62.30M
YoY Change -77.14% -7.29%
Accrued Expenses $28.14M
YoY Change 51.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $32.91M
YoY Change -10.88%
Total Short-Term Liabilities $70.63M $123.4M
YoY Change -42.77% 0.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $43.57M $211.0K
YoY Change 20549.76% -40.23%
Total Long-Term Liabilities $43.57M $211.0K
YoY Change 20549.76% -40.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.63M $123.4M
Total Long-Term Liabilities $43.57M $211.0K
Total Liabilities $114.3M $123.6M
YoY Change -7.57% 0.47%
SHAREHOLDERS EQUITY
Retained Earnings -$877.1M -$862.8M
YoY Change 1.66% 6.6%
Common Stock $1.224M $971.0K
YoY Change 26.06% 17.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$89.39M -$114.4M
YoY Change
Total Liabilities & Shareholders Equity $24.88M $9.240M
YoY Change 169.23% 30.62%

Cashflow Statement

Concept 2024 Q4 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.768M -$9.563M
YoY Change -50.14% -63.91%
Depreciation, Depletion And Amortization $4.000K $8.000K
YoY Change -50.0% -85.19%
Cash From Operating Activities -$2.502M
YoY Change -43.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 654.0K
YoY Change -71.97%
NET CHANGE
Cash From Operating Activities -2.502M
Cash From Investing Activities 0.000
Cash From Financing Activities 654.0K
Net Change In Cash -1.848M
YoY Change -10.85%
FREE CASH FLOW
Cash From Operating Activities -$2.502M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001175680
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20241130#AccruedCompensationAndNonFinancingLiabilities
CY2024Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2024Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20241130#AccruedCompensationAndNonFinancingLiabilities
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-49908
dei Entity Registrant Name
EntityRegistrantName
CYTODYN INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1887078
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Main Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 660
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98660
dei City Area Code
CityAreaCode
360
dei Local Phone Number
LocalPhoneNumber
980-8524
dei Security12b Title
Security12bTitle
None
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1228232000
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21335000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3110000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6704000
CY2024Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
635000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
463000
CY2024Q4 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
663000
CY2024Q2 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
538000
CY2024Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2000000
CY2024Q4 us-gaap Assets Current
AssetsCurrent
24633000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
10815000
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
321000
CY2024Q4 us-gaap Assets
Assets
24877000
CY2024Q2 us-gaap Assets
Assets
11136000
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14244000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29561000
CY2024Q4 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2767000
CY2024Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2810000
CY2024Q4 us-gaap Interest Payable Current
InterestPayableCurrent
17553000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
15227000
CY2024Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
7532000
CY2024Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
6791000
CY2024Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
28531000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
29793000
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70627000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
84182000
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2024Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43571000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43571000
CY2024Q4 us-gaap Liabilities
Liabilities
114267000
CY2024Q2 us-gaap Liabilities
Liabilities
127894000
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2311000
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1750000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1750000000
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1223517000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1059002000
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1223075000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058559000
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
1224000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1059000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3898000
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
786458000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
773714000
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-877072000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4999000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-891531000
CY2024Q4 cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
1409000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-89390000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-116758000
CY2023Q4 cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
1079000
cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
-22637000
cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
2993000
CY2024Q4 us-gaap Depreciation
Depreciation
4000
CY2023Q4 us-gaap Depreciation
Depreciation
8000
us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
18000
CY2024Q4 us-gaap Costs And Expenses
CostsAndExpenses
3707000
CY2023Q4 us-gaap Costs And Expenses
CostsAndExpenses
3398000
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24877000
us-gaap Costs And Expenses
CostsAndExpenses
-18730000
us-gaap Costs And Expenses
CostsAndExpenses
8010000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11136000
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2294000
cydy Gain Loss On Derivatives
GainLossOnDerivatives
-852000
cydy Gain Loss On Derivatives
GainLossOnDerivatives
-13000
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3707000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3398000
us-gaap Operating Income Loss
OperatingIncomeLoss
18730000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8010000
CY2024Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
142000
us-gaap Investment Income Interest
InvestmentIncomeInterest
268000
CY2024Q4 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1161000
CY2023Q4 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1164000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2326000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2361000
CY2024Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
113000
CY2023Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
142000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
238000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
542000
CY2023Q4 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
369000
CY2023Q4 cydy Issuance Costs For Private Placement Of Shares And Warrants Operating Activities
IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities
906000
cydy Issuance Costs For Private Placement Of Shares And Warrants Operating Activities
IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities
906000
CY2023Q4 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
636000
cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
1180000
cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2640000
CY2024Q4 cydy Finance Charge Adjustments
FinanceChargeAdjustments
9000
CY2023Q4 cydy Finance Charge Adjustments
FinanceChargeAdjustments
891000
cydy Finance Charge Adjustments
FinanceChargeAdjustments
23000
cydy Finance Charge Adjustments
FinanceChargeAdjustments
1803000
CY2023Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2406000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4490000
CY2024Q4 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
80000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
80000
CY2023Q4 cydy Gain Loss On Derivatives
GainLossOnDerivatives
-17000
CY2024Q4 cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-1061000
CY2023Q4 cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-6165000
cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-4271000
cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-13124000
CY2024Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4768000
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9563000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14459000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21134000
CY2024Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-4768000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-9563000
us-gaap Net Income Loss
NetIncomeLoss
14459000
us-gaap Net Income Loss
NetIncomeLoss
-21134000
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1221405000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
958988000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1177988000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
941191000
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1221405000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
958988000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1204193000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
941191000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-116758000
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000000
CY2024Q3 cydy Adjustments To Additional Paid In Capital Loss On Induced Conversion
AdjustmentsToAdditionalPaidInCapitalLossOnInducedConversion
-1180000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14026000
CY2024Q3 cydy Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Excluding Legal Fees
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsExcludingLegalFees
3649000
CY2024Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
372000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
136000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19227000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-85210000
CY2024Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
420000
CY2024Q4 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
369000
CY2024Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
537000
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-4768000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-89390000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-109501000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1500000
CY2023Q3 cydy Adjustments To Additional Paid In Capital Loss On Induced Conversion
AdjustmentsToAdditionalPaidInCapitalLossOnInducedConversion
-2004000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
170000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2023Q3 cydy Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
300000
CY2023Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
373000
CY2023Q3 cydy Reclassification Of Warrants From Liability To Equity Classified
ReclassificationOfWarrantsFromLiabilityToEquityClassified
79000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-116889000
CY2023Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
500000
CY2023Q4 cydy Adjustments To Additional Paid In Capital Loss On Induced Conversion
AdjustmentsToAdditionalPaidInCapitalLossOnInducedConversion
-636000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10000
CY2023Q4 cydy Note Conversion
NoteConversion
4393000
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
98000
CY2023Q4 cydy Adjustments To Additional Paid In Capital Stock To Be Issued For Private Offerings
AdjustmentsToAdditionalPaidInCapitalStockToBeIssuedForPrivateOfferings
6328000
CY2023Q4 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
368000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
474000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-9563000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-114381000
us-gaap Net Income Loss
NetIncomeLoss
14459000
us-gaap Net Income Loss
NetIncomeLoss
-21134000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
18000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
369000
cydy Issuance Costs For Private Placement Of Shares And Warrants Operating Activities
IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities
906000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
238000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
542000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
80000
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-852000
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-13000
cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
1180000
cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2640000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4490000
us-gaap Share Based Compensation
ShareBasedCompensation
673000
us-gaap Share Based Compensation
ShareBasedCompensation
1075000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2229000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
290000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-13248000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4374000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1854000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6997000
cydy Proceeds From Warrant Transactions Net
ProceedsFromWarrantTransactionsNet
10377000
cydy Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3016000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000
cydy Proceeds From Convertible Note And Warrant Issuances
ProceedsFromConvertibleNoteAndWarrantIssuances
1357000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
710000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9667000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4673000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11521000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2324000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9814000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9048000
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21335000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6724000
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21335000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6577000
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21335000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6724000
us-gaap Interest Paid Net
InterestPaidNet
23000
us-gaap Interest Paid Net
InterestPaidNet
38000
cydy Noncash Derivative Liability Associated With Warrants
NoncashDerivativeLiabilityAssociatedWithWarrants
80000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1420000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2000000
cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
741000
cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
741000
cydy Warrants Issued To Placement Agent
WarrantsIssuedToPlacementAgent
413000
cydy Note Conversion To Common Stock And Warrants
NoteConversionToCommonStockAndWarrants
2295000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
26205000
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1221405000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
958988000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1204193000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
941191000
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-877100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited consolidated financial statements have been prepared in accordance with GAAP, which requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and discussions with the U.S. Food and Drug Administration (“FDA”), which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include, but are not limited to, those relating to stock-based compensation, the assumptions used to value warrants, and warrant modifications. Actual results could differ from these estimates.</p>
CY2024Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
19100000
CY2024Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
214000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
208000
CY2024Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
111000
CY2024Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
7000
CY2024Q4 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
284000
CY2024Q2 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
329000
CY2024Q4 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
1875000
CY2024Q2 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
1799000
CY2024Q4 cydy Accrued Lease Payable
AccruedLeasePayable
141000
CY2024Q2 cydy Accrued Lease Payable
AccruedLeasePayable
142000
CY2024Q2 cydy Investor Proceeds Held In Escrow
InvestorProceedsHeldInEscrow
300000
CY2024Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
142000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000
CY2024Q4 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2767000
CY2024Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2810000
CY2024Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
28700000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30200000
CY2024Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
169000
CY2024Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
407000
CY2024Q4 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
28531000
CY2024Q2 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
29793000
CY2024Q4 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
17553000
CY2024Q2 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
15227000
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
46084000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
45020000
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
45020000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
238000
cydy Interest Expense Accrued
InterestExpenseAccrued
2326000
cydy Debt Conversion Fair Market Value Of Shares Exchanged For Repayment
DebtConversionFairMarketValueOfSharesExchangedForRepayment
1600000
cydy Changes In Fair Value Of Common Stocks Of Convertible Debt
ChangesInFairValueOfCommonStocksOfConvertibleDebt
100000
CY2024Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
46084000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
100000
CY2023Q2 cydy Number Of Share In Unit
NumberOfShareInUnit
1
CY2023Q2 cydy Number Of Warrant In Unit
NumberOfWarrantInUnit
1
CY2023Q2 cydy Deemed Purchase Price As Percentage Of Lower Intraday Volume Weighted Average Price
DeemedPurchasePriceAsPercentageOfLowerIntradayVolumeWeightedAveragePrice
0.90
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.306
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.5
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127100000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.09387
CY2024Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11900000
CY2024Q3 cydy Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
10400000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
25400000
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1400000
CY2024Q3 cydy Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.13
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.09387
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1400000
CY2024Q3 us-gaap Legal Fees
LegalFees
100000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1700000
CY2024Q3 cydy Fair Value Adjustment Of Warrants Repricing
FairValueAdjustmentOfWarrantsRepricing
400000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
361445
CY2024Q2 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.34
CY2024 cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y2M15D
CY2024Q2 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
2697000
cydy Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
127087
CY2024Q4 cydy Class Of Warrants Or Rights Exercised Weighted Average Exercise Price
ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice
0.09
cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled
4729
CY2024Q4 cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice
0.37
CY2024Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
229629
CY2024Q4 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.26
cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y29D
CY2024Q4 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
1269000
cydy Class Of Warrant Or Right Outstanding And Exercisable
ClassOfWarrantOrRightOutstandingAndExercisable
229629
CY2024Q4 cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageExercisePrice
0.26
cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P4Y29D
CY2024Q4 cydy Class Of Warrants Or Rights Outstanding And Exercisable Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAndExercisableAggregateIntrinsicValue
1269000
cydy Share Based Compensation Number Of Active Plans
ShareBasedCompensationNumberOfActivePlans
1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.23
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-4768000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-9563000
us-gaap Net Income Loss
NetIncomeLoss
14459000
us-gaap Net Income Loss
NetIncomeLoss
-21134000
CY2024Q4 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
369000
CY2023Q4 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
368000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
741000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
741000
CY2024Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5137000
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9931000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13718000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21875000
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1221405000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
958988000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1177988000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
941191000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
32000
CY2023Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
32000
us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
264000
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
141000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
142000
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
210000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
283000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
92000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
169000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
261000
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
51000
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
210000
CY2024Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2024Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
cydy Commitments With Contract Research Organization Maximum Cancellation Fee Percentage
CommitmentsWithContractResearchOrganizationMaximumCancellationFeePercentage
0.05

Files In Submission

Name View Source Status
0001558370-25-000207-index-headers.html Edgar Link pending
0001558370-25-000207-index.html Edgar Link pending
0001558370-25-000207.txt Edgar Link pending
0001558370-25-000207-xbrl.zip Edgar Link pending
cydy-20241130.xsd Edgar Link pending
cydy-20241130x10q.htm Edgar Link pending
cydy-20241130xex31d1.htm Edgar Link pending
cydy-20241130xex31d2.htm Edgar Link pending
cydy-20241130xex32.htm Edgar Link pending
cydy-20241130_lab.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cydy-20241130_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cydy-20241130_def.xml Edgar Link unprocessable
cydy-20241130x10q_htm.xml Edgar Link completed
cydy-20241130_cal.xml Edgar Link unprocessable